Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
CooperCompanies (Nasdaq: COO) is a global medical device company with two main business units, CooperVision and CooperSurgical, and its news flow reflects this mix of vision care and women’s health activities. Company press releases regularly provide updates on quarterly and annual financial results, including revenue, earnings per share, margins, and free cash flow, along with commentary from management on operational performance and priorities.
Investors following COO news will see detailed segment information for CooperVision and CooperSurgical, such as revenue by product category and geography, as well as explanations of non‑GAAP metrics, constant currency growth, and organic growth. Releases also describe reorganization and integration efforts, business optimization charges, and product line exits, offering context on how these actions affect reported margins and future cost structure.
CooperCompanies’ news also covers corporate governance and strategic topics. Recent announcements include changes in Board leadership, the appointment of new independent directors, and a formal strategic review of the company’s businesses, corporate structure, and capital allocation priorities. The company has disclosed cooperation agreements with investment partners and expansions of its share repurchase program, including a Board‑approved increase that brought total authorization to $2 billion.
In addition, CooperCompanies issues notices about upcoming earnings releases, conference calls, and participation in healthcare investment conferences, where senior executives present and answer questions. For those interested in the broader eye care landscape, external communications related to CooperVision highlight its role in contact lenses and myopia management. This news page brings together these financial, strategic, and industry‑related updates in one place for users tracking COO.
CooperCompanies (NYSE: COO) announced key leadership changes to enhance organizational growth. Effective February 1, 2022, Dan McBride, currently EVP and COO, will expand his role to include global leadership of human resources, legal, and corporate strategy, while maintaining oversight of CooperVision. Jerry Warner, previously EVP for Americas and Global Commercial Functions, will be promoted to President of CooperVision, managing all global functions within the unit. This restructuring aims to leverage industry expertise and strengthen strategic direction amid the company's growth trajectory.
Generate Life Sciences announces its agreement to be acquired by CooperCompanies (NYSE: COO), aiming to enhance CooperSurgical's capabilities in women's health and fertility. This strategic acquisition allows Generate to leverage CooperSurgical's global network in over 100 countries, increasing access to innovative reproductive and genetic services. Generate's products complement CooperSurgical's current offerings, potentially leading to improved patient options in assisted reproductive technology. The transaction awaits regulatory approval, with closing anticipated in Cooper's Fiscal first quarter.
GI Partners has signed a definitive agreement to sell Generate Life Sciences, a leader in reproductive and newborn stem cell services, to CooperCompanies (NYSE:COO). Generate Life Sciences, formed in 2018, combines industry leaders California Cryobank Life Sciences and Cord Blood Registry, serving nearly one million families globally. The transaction, which is subject to customary closing conditions, is expected to finalize in December 2021. This acquisition aims to enhance CooperCompanies' offerings in reproductive and genetic services, further expanding its global reach.
CooperCompanies (NYSE: COO) has announced its acquisition of Generate Life Sciences for approximately $1.6 billion. This strategic acquisition enhances CooperSurgical’s portfolio in fertility and newborn stem cell services, enabling better support for fertility clinics and Ob/Gyns. Generate Life Sciences, which reported $250 million in revenues over the last year, is projected to contribute $0.30 to Cooper’s non-GAAP earnings per share in the first year post-acquisition. The deal is set to close in early 2022, pending regulatory approval.
CooperCompanies (NYSE: COO) announced it will release its fourth quarter and full year 2021 financial results on December 2, 2021, at 4:15 PM ET. A conference call to discuss the results will follow at 5:00 PM ET. Interested parties can join by dialing 855-643-4430 (U.S.) or 707-294-1332 (International), using the passcode 'Cooper'. The call will be streamed live via the Investor Relations section of the CooperCompanies website and recorded for later access.
CooperVision, based in San Ramon, Calif., launched a new initiative called "Take Control: Myopia & You" aimed at raising awareness about childhood myopia. This initiative is a response to rising cases of myopia, potentially worsened by increased screen time during the COVID-19 pandemic. The campaign emphasizes the efficacy of MiSight® 1 day contact lenses, which significantly slow myopia progression in children aged 8-12. Spokespersons include young actor Alan Kim and actress Madison Reyes, promoting the program's benefits through direct personal experiences.
Summary not available.
CooperCompanies (NYSE: COO) reported a strong fiscal Q3 2021, with revenues increasing by 32% year-over-year to $763.4 million. CooperVision's revenue grew by 24% to $557.5 million, while CooperSurgical saw a remarkable 60% increase to $205.9 million. GAAP diluted earnings per share reached $12.37, a substantial rise from $11.25 in Q3 2020. The company highlighted record performances in both segments, driven by product success and robust cash flow. The fiscal year 2021 guidance has been updated, projecting total revenues of $2.893 to $2.923 billion, reflecting continued growth potential.
CooperVision Canada announces a new campaign featuring pop singer Mitsou Gélinas to raise awareness about children's myopia. The initiative aims to educate parents in Québec on the increase in near vision activities among children, especially post-pandemic, where 59% of parents reported more screen time. The campaign will include advertising and social media collaboration, emphasizing the significance of eye exams before school starts. CooperVision's Brilliant Futures™ Myopia Management Program and its MiSight® 1 day contact lenses are highlighted as effective solutions for managing myopia in children.
CooperCompanies (NYSE: COO) will participate in the Virtual Wells Fargo Healthcare Conference on September 10, 2021, at 1:20 PM ET. Al White, President and CEO, will represent the company in a virtual session. A live webcast can be accessed via the Investor Relations section of CooperCompanies’ website, with a replay available 48 hours post-event. Cooper operates globally with two main divisions: CooperVision, focusing on vision care products, and CooperSurgical, dedicated to women's health. The company is headquartered in San Ramon, CA, employing over 12,000 individuals.
FAQ
What is the current stock price of Cooper (COO)?
What is the market cap of Cooper (COO)?
